Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.
Condition(s):Lung NeoplasmsLast Updated:April 20, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Lung NeoplasmsLast Updated:April 20, 2022Recruiting
Condition(s):Diabetes Mellitus, Type 1Last Updated:February 15, 2024Recruiting
Condition(s):Small-cell Lung Cancer; Small Cell Lung CarcinomaLast Updated:March 1, 2024Not yet recruiting
Condition(s):Myelofibrosis; Moderate ThrombocytopeniaLast Updated:February 1, 2024Not yet recruiting
Condition(s):HealthyLast Updated:June 5, 2012Completed
Condition(s):HealthyLast Updated:June 5, 2012Completed
Condition(s):NSCLCLast Updated:January 6, 2020Unknown status
Condition(s):Atopic DermatitisLast Updated:April 13, 2022Completed
Condition(s):EGFR Inhibitor Induced Acneiform LesionsLast Updated:April 6, 2022Completed
Condition(s):CancerLast Updated:April 15, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.